PDF(Pubmed)
Abstract：
UNASSIGNED: Articular manifestations have been reported in 19.3%-53.5% of patients with primary Sjogren\'s syndrome. Our aim was to profile the clinical characteristics of Chinese patients with primary Sjogren\'s syndrome who presented with articular manifestations at the time of initial treatment.
UNASSIGNED: We conducted a retrospective study of 129 primary Sjogren\'s syndrome patients admitted to the second Affiliated Hospital of Dalian Medical University between April 2016 and December 2021 for initial treatment. Clinical and serological features, extra-articular involvement, and initial treatment were compared between primary Sjogren\'s syndrome patients with and without articular manifestations.
UNASSIGNED: Fifty-seven (44.2%) primary Sjogren\'s syndrome patients had articular manifestations (mean age at diagnosis: 53.4 years), of which 42 (73.7%) presented with symmetrical distribution, 21 (36.8%) patients had rheumatoid factor positivity, and 11 (20.0%) patients had anti-cyclic citrullinated peptide antibodies positivity (mean 6.8 RU/mL); imaging examinations showed no signs of structural damage in these patients. The presence of articular manifestations showed positive correlation with anti-cyclic citrullinated peptide antibody level (odds ratio (OR) 1.01, 95% confidence interval (CI): 1.00-1.02; p = 0.049), C-reactive protein level (OR 1.15, 95% CI: 1.10-1.20; p = 0.000), and European League Against Rheumatism Sjogren syndrome disease activity index scores (OR 1.18, 95% CI: 1.11-1.25; p = 0.000). Ninety (69.8%) primary Sjogren\'s syndrome patients received hydroxychloroquine therapy. Hydroxychloroquine treatment was significantly less frequently used in articular manifestation patients (35 (70.0%) vs 55 (85.9%); p = 0.038).
UNASSIGNED: Symmetrical polyarthritis was the most common clinical manifestation of primary Sjogren\'s syndrome patients with articular manifestations in this cohort. Articular manifestations were associated with higher prevalence of C-reactive protein level, and European League Against Rheumatism Sjogren syndrome disease activity index score.
UNASSIGNED: We conducted a retrospective study of 129 primary Sjogren\'s syndrome patients admitted to the second Affiliated Hospital of Dalian Medical University between April 2016 and December 2021 for initial treatment. Clinical and serological features, extra-articular involvement, and initial treatment were compared between primary Sjogren\'s syndrome patients with and without articular manifestations.
UNASSIGNED: Fifty-seven (44.2%) primary Sjogren\'s syndrome patients had articular manifestations (mean age at diagnosis: 53.4 years), of which 42 (73.7%) presented with symmetrical distribution, 21 (36.8%) patients had rheumatoid factor positivity, and 11 (20.0%) patients had anti-cyclic citrullinated peptide antibodies positivity (mean 6.8 RU/mL); imaging examinations showed no signs of structural damage in these patients. The presence of articular manifestations showed positive correlation with anti-cyclic citrullinated peptide antibody level (odds ratio (OR) 1.01, 95% confidence interval (CI): 1.00-1.02; p = 0.049), C-reactive protein level (OR 1.15, 95% CI: 1.10-1.20; p = 0.000), and European League Against Rheumatism Sjogren syndrome disease activity index scores (OR 1.18, 95% CI: 1.11-1.25; p = 0.000). Ninety (69.8%) primary Sjogren\'s syndrome patients received hydroxychloroquine therapy. Hydroxychloroquine treatment was significantly less frequently used in articular manifestation patients (35 (70.0%) vs 55 (85.9%); p = 0.038).
UNASSIGNED: Symmetrical polyarthritis was the most common clinical manifestation of primary Sjogren\'s syndrome patients with articular manifestations in this cohort. Articular manifestations were associated with higher prevalence of C-reactive protein level, and European League Against Rheumatism Sjogren syndrome disease activity index score.
摘要：
■据报道，有19.3％-53.5％的原发性干燥综合征患者有关节表现。我们的目的是描述中国原发性干燥综合征患者的临床特征，这些患者在初始治疗时有关节表现。
我们对大连医科大学附属第二医院2016年4月至2021年12月间收治的129例原发性干燥综合征患者进行了回顾性研究。临床和血清学特征，关节外受累,比较有和没有关节表现的原发性干燥综合征患者的初始治疗。
■57例（44.2%）原发性干燥综合征患者有关节表现（诊断时平均年龄：53.4岁），其中42人(73.7%)呈对称分布，21例（36.8%）患者有类风湿因子阳性，11例（20.0％）患者的抗环瓜氨酸肽抗体阳性（平均6.8RU/mL）；影像学检查显示这些患者没有结构损伤的迹象。关节表现与抗环瓜氨酸肽抗体水平呈正相关(比值比(OR)1.01,95%置信区间(CI):1.00-1.02;p=0.049),C反应蛋白水平（OR1.15，95％CI：1.10-1.20；p=0.000），和欧洲抗风湿病干燥综合征疾病活动指数得分（OR1.18，95％CI：1.11-1.25；p=0.000）。90例(69.8%)原发性干燥综合征患者接受羟氯喹治疗。关节表现患者使用羟氯喹治疗的频率明显较低（35（70.0％）vs55（85.9％）；p=0.038）。
■对称性多关节炎是原发性干燥综合征患者最常见的临床表现。关节表现与C反应蛋白水平较高的患病率相关。和欧洲抗风湿病联盟干燥综合征疾病活动指数评分。
我们对大连医科大学附属第二医院2016年4月至2021年12月间收治的129例原发性干燥综合征患者进行了回顾性研究。临床和血清学特征，关节外受累,比较有和没有关节表现的原发性干燥综合征患者的初始治疗。
■57例（44.2%）原发性干燥综合征患者有关节表现（诊断时平均年龄：53.4岁），其中42人(73.7%)呈对称分布，21例（36.8%）患者有类风湿因子阳性，11例（20.0％）患者的抗环瓜氨酸肽抗体阳性（平均6.8RU/mL）；影像学检查显示这些患者没有结构损伤的迹象。关节表现与抗环瓜氨酸肽抗体水平呈正相关(比值比(OR)1.01,95%置信区间(CI):1.00-1.02;p=0.049),C反应蛋白水平（OR1.15，95％CI：1.10-1.20；p=0.000），和欧洲抗风湿病干燥综合征疾病活动指数得分（OR1.18，95％CI：1.11-1.25；p=0.000）。90例(69.8%)原发性干燥综合征患者接受羟氯喹治疗。关节表现患者使用羟氯喹治疗的频率明显较低（35（70.0％）vs55（85.9％）；p=0.038）。
■对称性多关节炎是原发性干燥综合征患者最常见的临床表现。关节表现与C反应蛋白水平较高的患病率相关。和欧洲抗风湿病联盟干燥综合征疾病活动指数评分。
